You are here:

Docetaxel 20mg, 80mg concentrate and solvent for solution for infusion, single dose vials (Taxotere®)

Advice

Following a full submission

Docetaxel (Taxotere) is accepted for use within NHS Scotland in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of operable, node-positive breast cancer.

Docetaxel in combination with doxorubicin and cyclophosphamide was associated with a significant improvement in disease free survival at 5 years when compared with one of the standard treatment regimens. However, this benefit is associated with an increased risk of toxicity. Docetaxel has demonstrated cost effectiveness in comparison to standard treatment regimen used in NHS Scotland

Drug Details

Drug Name: Docetaxel 20mg, 80mg concentrate and solvent for solution for infusion, single dose vials (Taxotere®)
SMC Drug ID: 201/05
Manufacturer: Sanofi-Aventis
Indication: Operable, node-positive breast cancer
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 10 October 2005

Back